Faasi 3, n=490. SCLC 1. linja: atetsolitsumabi + KAR-E x 4 + tiragolumabi / plasebo -> atetsolitsumabi + tiragolumabi/plasebo -ylläpitohoito.

PFS 14.3 kk vs. 13. 9 kk ei eroa, OS 13.1 kk molemmissa ryhmissä.

https://ascopubs.org/doi/10.1200/JCO.23.01363 SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer